ArticleBMC public health2026
Content analysis of illegal online advertisements for hypertension-related drugs and supplements in Taiwan.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is a prevalent chronic condition globally and in Taiwan, requiring long-term treatment and ongoing health management. Despite this, online and social media platforms have increasingly become channels for illegal advertisements of products claiming to lower blood pressure or improve cardiovascular health, which may be associated with patients' health expectations and decision-making.
objectiveThis study aimed to examine the content of illegal advertisements for drugs and health supplements targeting individuals with hypertension in Taiwan and to identify their persuasive strategies and potential associated risks.
methodsBetween September and November 2024, a total of 19 eligible illegal advertisements were collected through targeted online searches of Taiwan-based websites. The Public Disclosure Section for Misleading Advertisements provided by the national regulatory authority was used as a reference for identifying potential violation patterns. A qualitative content analysis was conducted, and advertisements were coded using predefined operational definitions.
resultsThree primary persuasive themes emerged from the analysis: authority-based appeals, efficacy-focused claims, and emotional strategies. Each theme comprised two categories: professional endorsement and certification (authority-based), promises of quick results and misleading claims of full recovery (efficacy-focused), and patient testimonials and celebrity endorsements (emotional). Advertisements employed multiple strategies simultaneously. Professional endorsement and certification were the most frequently observed authority-based cues within the collected advertisement corpus. Claims of quick results and full recovery may contribute to unrealistic expectations regarding disease treatment among patients and could obscure potential health risks. Patient testimonials and celebrity endorsements could appear to influence consumer behavior through emotional appeals. Overall, advertisements lacked transparent risk disclosures and credible scientific evidence.
conclusionsThis study identifies the strategic use of authority, efficacy, and emotional appeals in illegal online advertisements for hypertension-related products, may be relevant to consumer protection considerations. Regulatory authorities should strengthen real-time monitoring and enforce transparent information disclosure to protect vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.